Haloperidol
- Generic Name
- Haloperidol
- Brand Names
- Haldol
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23ClFNO2
- CAS Number
- 52-86-8
- Unique Ingredient Identifier
- J6292F8L3D
- Background
Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularl...
- Indication
Haloperidol is indicated for a number of conditions including for the treatment of schizophrenia, for the manifestations of psychotic disorders, for the control of tics and vocal utterances of Tourette’s Disorder in children and adults, for treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted ...
- Associated Conditions
- Aggression, Delirium, Gilles de la Tourette's Syndrome, Huntington's Disease (HD), Nausea and vomiting, Obsessive Compulsive Disorder (OCD), Psychosis, Schizophrenia, Severe Disruptive Behaviour Disorders, Severe Hyperactivity
- Associated Therapies
- -
Comparative Efficacy of Dexamethasone - Ondansetron Versus Dexamethasone - Haloperidol in Reducing PONV
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Universitas Padjadjaran
- Target Recruit Count
- 38
- Registration Number
- NCT06428084
- Locations
- 🇮🇩
Hasan Sadikin General Hospital, Bandung, West Java, Indonesia
Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department
- Conditions
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Western Michigan University School of Medicine
- Target Recruit Count
- 75
- Registration Number
- NCT06395428
- Locations
- 🇺🇸
Bronson Methodist Hospital, Kalamazoo, Michigan, United States
Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult
- Conditions
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-22
- Target Recruit Count
- 60
- Registration Number
- NCT06370442
A Study of Olanzapine in Patients With Acute Agitation
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 318
- Registration Number
- NCT05803642
Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 100
- Registration Number
- NCT05690698
- Locations
- 🇪🇬
Faculty of Medicine, Alexandria University Hospitals, Alexandria, Egypt
Managing Agitated Delirium with Neuroleptics and Anti-Epileptics As a Neuroleptic Sparing Strategy
- Conditions
- Interventions
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05431595
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis
- Conditions
- Interventions
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Spectrum Health - Lakeland
- Target Recruit Count
- 38
- Registration Number
- NCT05065567
- Locations
- 🇺🇸
Lakeland Regional Healthcare, Saint Joseph, Michigan, United States
Haloperidol for the Treatment of Nausea and Vomiting in the ED
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Western Michigan University School of Medicine
- Target Recruit Count
- 60
- Registration Number
- NCT04764344
- Locations
- 🇺🇸
Bronson Methodist Hospital, Kalamazoo, Michigan, United States
Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose
- Conditions
- Interventions
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- InterveXion Therapeutics, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT04715230
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Sacred Heart Medical Center, Spokane, Washington, United States
🇺🇸University of New Mexico Hospital, Albuquerque, New Mexico, United States
Treatment Strategies in CHS
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 4
- Registration Number
- NCT04176055
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.